[Form 4] iTeos Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

iTeos Therapeutics insider reporting linked to merger consideration

David Feltquate, Chief Medical Officer of iTeos Therapeutics (ITOS), reported a disposition on 08/29/2025 of 47,000 restricted stock units that became vested and were canceled under the Agreement and Plan of Merger with Concentra Biosciences LLC. In exchange for canceled units, holders were entitled to $10.047 in cash per share (subject to tax withholding) and one non-transferable contractual contingent value right per share. The Form 4 shows the reporter held 0 shares following the transaction. The filing was signed by an attorney-in-fact, Adi Osovsky.

Positive

• Recipients received cash consideration of $10.047 per share for canceled restricted stock units
• Holders also received one non-transferable contingent value right per share, preserving potential upside beyond the cash payment

Negative

• Reporting person’s beneficial ownership reduced to 0 shares following the merger-related cancellation
• 47,000 restricted stock units were canceled, eliminating future equity upside tied to those units for the reporting person

Insights

Corporate Governance Expert

TL;DR: Insider equity awards were accelerated and converted to merger consideration, eliminating reported holdings.

The filing documents a routine merger-related accelerated vesting and cash-out of time-based restricted stock units for an executive. From a governance perspective, the Compensation and Leadership Development Committee approved treatment consistent with the Merger Agreement, converting vested awards into cash and contingent value rights. This is a standard exit treatment that aligns executive compensation outcomes with transaction terms; it reduces insider equity exposure post-close and crystallizes value for award holders.

M&A Specialist

TL;DR: Transaction reflects customary merger mechanics: tender/merger, accelerated vesting, cash consideration plus CVRs.

The Form 4 confirms that the Merger Agreement provided for accelerated vesting of qualifying restricted stock units, cancellation of those units, and payout of specified cash consideration of $10.047 per share plus one contingent value right per share. This treatment is consistent with a cash-centric purchase with retained contingent upside via CVRs and illustrates how equity-based compensation was settled at close.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Feltquate David

(Last) (First) (Middle)

C/O ITEOS THERAPEUTICS, INC.

321 ARSENAL STREET

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
iTeos Therapeutics, Inc. [ ITOS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/29/2025		U(1)(2)(3)		47,000	D	(1)(2)(3)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the "Company"), Concentra Biosciences LLC ("Parent"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Parent completed a tender offer for shares of common stock of the Company and thereafter, the Merger Sub merged with and into the Company (the "Merger"). The amount reported in Column 4 includes 47,000 restricted stock units of the Company ("Company Restricted Stock Units," and each such restricted stock unit, a "Company Restricted Stock Unit").

2. (Continued from footnote 1) Pursuant to the actions of the of the Compensation and Leadership Development Committee of the Board of Directors of the Company and in accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, (A) each Company Restricted Stock Unit that was held by a Company service provider who was subject to an individual employment or other agreement and/or a Company severance and change in control plan or agreement that provides for accelerated vesting of time-based equity awards upon the occurrence of a sale of the Company or a qualifying termination of employment or service in connection with, or within a specified time following, a sale of the Company (each such Company Restricted Stock Unit, an "Accelerated Vesting Restricted Stock Unit")

3. (Continued from footnote 2) that was then outstanding but not then vested became immediately vested in full and (B) each Accelerated Vesting Restricted Stock Unit that was then outstanding was canceled and, in exchange therefor, the holder of such canceled Company Restricted Stock Unit became entitled to receive in consideration of the cancellation of such Company Restricted Stock Unit (x) an amount in cash without interest, subject to any applicable tax withholding, equal to $10.047 in cash per share and (y) one non-transferable contractual contingent value right per share.

	/s/ Adi Osovsky, as Attorney-in-Fact	08/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did David Feltquate report on Form 4 for ITOS?

The Form 4 reports disposition of 47,000 restricted stock units on 08/29/2025 related to the merger, with 0 shares held afterwards.

Why were the restricted stock units disposed of in the Form 4?

The units were canceled and settled pursuant to the Agreement and Plan of Merger with Concentra Biosciences LLC, following accelerated vesting provisions.

What consideration did holders receive for canceled restricted stock units?

Holders were entitled to $10.047 in cash per share (subject to tax withholding) and one non-transferable contractual contingent value right per share.

When did the reported transaction occur?

The transaction date reported on the Form 4 is 08/29/2025.

Who signed the Form 4 filing?

The Form 4 was signed by Adi Osovsky as attorney-in-fact on behalf of the reporting person on 08/29/2025.